← TENAX THERAPEUTICS, INC. (TENX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
TENAX THERAPEUTICS, INC. (TENX)
Pharmaceutical Preparations · market cap $70M · as of 2026-07-10
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-11 (est.)
Earnings
Pipeline
4
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Tenax Therapeutics (TENX) is a small-cap clinical-stage pharma (4 employees, ~$470M market cap) focused on cardiovascular and pulmonary diseases. Its lead asset TNX-103 is in Phase 3 for Pulmonary Hypertension, with a pivotal readout expected around October 2026. The company carries $118.8M in cash with a ~38-month runway and zero revenue.
The catalyst path
- 2026-11-11 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Levosimendan | Phase 2 | Hypertension Pulmonary Secondary |
| perfluorocarbon emulsion (Oxycyte) infusion | Phase 2 | Traumatic Brain Injury |
| Levosimendan 2.5 mg/ml Injectable Solution | Phase 2 | Hypertension Pulmonary Secondary Heart Failure |
| TNX-103 | Phase 3 | Pulmonary Hypertension |
Price & technical context
3-month
-87.5%
6-month
-87.9%
12-month
-74.6%
52-wk range
$1.38–$18.32
vs 50-day MA
-60.4%
vs 200-day MA
-82.8%
Realized vol
243.1%
Max drawdown
-92.5%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for TENX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.